Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators

    Authors: Kirill Gorshkov; Catherine Z. Chen; Robert Bostwick; Lynn Rasmussen; Miao Xu; Manisha Pradhan; Bruce Nguyen Tran; Wei Zhu; Khalida Shamim; Wenwei Huang; Xin Hu; Min Shen; Carleen Klumpp-Thomas; Zina Itkin; Paul Shinn; Anton Simeonov; Sam Michael; Matthew D. Hall; Donald C. Lo; Wei Zheng

    doi:10.1101/2020.05.16.091520 Date: 2020-05-21 Source: bioRxiv

    SARS-CoV-2 is a new type of coronavirus capable of rapid transmission and causing severe clinical symptoms; much of which has unknown biological etiology. It has prompted researchers to rapidly mobilize their efforts towards identifying and developing anti-viral therapeutics and vaccines. Discovering and understanding the virus’ pathways of infection, host-protein interactions, and cytopathic effects will greatly aid in the design of new therapeutics to treat COVID-19 MESHD. While it is known that chloroquine and hydroxychloroquine, extensively explored as clinical agents for COVID-19 MESHD, have multiple cellular effects including inhibiting autophagy, there are also dose-limiting toxicities MESHD in patients that make clearly establishing their potential mechanisms-of-action problematic. Therefore, we evaluated a range of other autophagy modulators to identify an alternative autophagy-based drug repurposing opportunity. In this work, we found that 6 of these compounds blocked the cytopathic effect of SARS-CoV-2 in Vero-E6 cells with EC50 values ranging from 2.0 to 13 µM and selectivity indices ranging from 1.5 to >10-fold. Immunofluorescence staining for LC3B HGNC and LysoTracker dye staining assays in several cell lines indicated their potency and efficacy for inhibiting autophagy correlated with the measurements in the SARS-CoV-2 cytopathic effect assay. Our data suggest that autophagy pathways could be targeted to combat SARS-CoV-2 infections MESHD SARS-CoV-2 infections MESHD and become an important component of drug combination therapies to improve the treatment outcomes for COVID-19 MESHD.One Sentence Summary Blocking SARS-CoV-2 cytopathic effects with selective autophagy inhibitors underlying the clinical benefits of chloroquine and hydroxychloroquine.Competing Interest StatementThe authors have declared no competing interest.View Full Text

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.